✓ Last verified: March 2, 2026 — Edited & verified by Angelica Bottaro for HealingMaps Editorial Staff
Known For: Insurance-covered Spravato provider in western South Dakota. Newer Rapid City location serving the Black Hills communities. Also offers TMS therapy.
| Review Scores | Opened late 2025 (ribbon cutting October 2025) |
| Location | Rapid City, SD |
| Address | 2620 Jackson Blvd, Suite G, Rapid City, SD 57702 |
| Phone | (605) 600-7880 |
| Website | mwihealth.org |
| Treatments | Spravato (Esketamine Nasal Spray), TMS Therapy, Psychiatric Evaluation, Medication Management |
| Conditions Treated | Treatment-Resistant Depression, Anxiety, ADD/ADHD |
| Cost | Contact clinic for pricing |
| Insurance | Spravato is FDA-approved and often covered by insurance |
| Clinical Lead | MWI Health psychiatric team |
HealingMaps Take: MWI Health fills a critical gap in western South Dakota: an insurance-friendly Spravato provider with TMS therapy also available. While Blossom Health & Wellness serves the Rapid City area with IV ketamine (which is typically out-of-pocket), MWI Health offers the FDA-approved Spravato pathway — which is far more likely to be covered by insurance. For patients whose primary barrier to treatment has been cost, MWI Health may be the more accessible option. The clinic opened in late 2025, with a ribbon cutting in October, making it one of the newest mental health facilities in the region. Beyond Spravato, the practice offers TMS (transcranial magnetic stimulation), psychiatric evaluations, and medication management — a well-rounded interventional psychiatry menu. The combination of Spravato and TMS means patients in the Black Hills corridor now have access to two distinct, evidence-based, insurance-coverable treatment modalities without leaving Rapid City.
Market Position: MWI Health is a Spravato-certified clinic in the City metro. Spravato (esketamine) is the FDA-approved ketamine treatment that most commercial insurance plans cover after prior authorization — unlike cash-pay IV ketamine.
Industry pricing reference. MWI Health has not published specific per-session pricing — contact the clinic directly for a quote. The calculator above shows typical metro-level cost estimates across protocols, not this clinic’s specific prices.
| Protocol | Typical Industry Cost | Offered Here |
|---|---|---|
| IV Ketamine | $350–$650/session | — |
| Spravato (esketamine) | $0–$250 copay (insured) | ✓ Yes |
| IM Ketamine | $250–$400/injection | — |
| KAP (with therapist) | $400–$1,200/session | — |
| At-home troches | $150–$300/month | — |
Sources: CDC PLACES 2023 (Pennington County, SD, crude prevalence) · U.S. Census ACS 5 Year · HealingMaps proprietary patient inquiry data.
Behind this data: HealingMaps has analyzed 23,496 patient inquiries (Oct 2022 – Mar 2026), mapped 1,473 verified clinics across 3,142 counties, scraped 132 clinic pricing pages, and collected 658 practitioner survey responses. This snapshot reflects our multi-source methodology.
Treatment-resistant depression — typically defined as failure on two or more antidepressant trials — is the FDA-approved indication for Spravato and the most common clinical qualifier for ketamine therapy insurance coverage. Source: HealingMaps 2026 Ketamine Clinic Intelligence Report — drawn from 23,496 patient inquiries and 132 clinic website analyses.
This 3-question summary is matched to the protocols and conditions MWI Health treats. Editorial responses are HealingMaps-authored, grounded in our 2026 Ketamine Clinic Intelligence Report.
Yes — MWI Health offers Spravato, which means they’re FDA REMS-certified and maintain the required two-hour in-office monitoring window after each dose. Spravato is the primary insurance-covered ketamine option for treatment-resistant depression. Worth confirming the prior-authorization timeline before booking your first session.
MWI Health treats depression via Spravato (FDA-approved for TRD). The Spravato pathway is the most likely to obtain commercial insurance coverage. TRD is typically defined as two or more prior antidepressant trials without sufficient response — patients meeting that bar are best candidates here.
Yes — MWI Health treats anxiety, including generalized anxiety, social anxiety, and panic disorder. The evidence base for ketamine in anxiety is less robust than for depression, but it can be a meaningful option for patients who haven’t responded to SSRIs or benzodiazepines. Worth asking which of their protocols they typically recommend for anxiety-primary patients.
Leave a Reply